ELISA kits for therapeutic and biosimilar antibodies
Related
Find the right kit to measure biosimilar antibodies or related anti-drug antibodies in human serum and plasma
Take a look at our range of ELISA kits for the detection and quantification of therapeutic monoclonal antibodies such as Herceptin®, biosimilars including Rituximab and Adalimumab, and immunogenicity assays for anti-drug antibody (ADA) analysis.
Our dedicated range of ELISA kits are:
- Accurate: low intra and inter-assay variability
- Highly sensitive
- Specific: no cross-reactivity with other human serum proteins or other therapeutic immunoglobulins
Take a look at our range of:
Therapeutic monoclonal antibody (mAb) and biosimilar ELISA kits
Therapeutic monoclonal antibodies (mAbs) and biosimilars
Therapeutic or monoclonal antibody therapy uses antibodies directed against specific proteins on certain cells to invoke an immune response against that protein or cell type. This means that these antibodies can be used to target and attack unwanted cell types in the body. So far this method of treatment has been extremely successful for many diseases including cancer and Alzheimers.
Biosimilar antibodies are antibodies almost identical to their therapeutic counterpart, serving the exact same therapeutic function. These antibodies are however not yet FDA approved and may only be of use in a clinical setting once the patent has run out on the original approved therapeutic antibody. This can make biosimilar antibodies advantageous as they are not as expensive and easier to obtain.
Bridging ELISA kits for the quantification of monoclonal therapeutic antibodies and biosimilars:
AbId | Product Name | Sensitivity (ng/mL) | Detection range (ng/mL) |
Rituximab ELISA Kit (Mabthera®) | 3 | 3 - 300 | |
Adalimumab ELISA Kit (Humira®) | 10 | 30 - 1000 | |
Bevacizumab ELISA Kit (Avastin®) | 30 | 30 - 1000 | |
Etanercept ELISA Kit (Enbrel®) | 100 | 100 - 3000 | |
Infliximab ELISA Kit (Remicade®) | 30 | 100 - 3000 | |
Trastuzumab ELISA Kit (Herceptin®) | 11 | 11 - 300 | |
Golimumab ELISA Kit (Simponi®) | 100 | 100 - 3000 | |
Infliximab ELISA Kit (Remsima®) | 30 | 100 - 3000 | |
Cetuximab ELISA Kit (Erbitux®) | 100 | 100 - 3000 | |
Denosumab ELISA Kit (Prolia®) | 3 | 3 - 300 | |
Omalizumab ELISA Kit (Xolair®) | 10 | 30 - 1000 | |
Nivolumab ELISA Kit (Opdivo®) | 10 | 30 - 3000 | |
Pembrolizumab ELISA Kit (Keytruda®) | 10 | 30 - 1000 | |
Ipilimumab ELISA Kit (Yervoy®) | 10 | 10 - 1000 | |
Avelumab ELISA Kit (Bavencio®) | 30 | 100 - 3000 |
Anti-drug antibodies
Anti-drug antibodies (ADA) are unwanted antibodies produced by the body's own immune system in response to therapeutic antibody treatment. This will have a negative effect on the treatment and may even result in adverse side effects including autoimmune response. Monitoring the level of anti-drug antibodies is important to fully understand these adverse drug reactions.
Bridging ELISA kits to detect and or quantify anti-drug antibodies:
AbID | Product Name | Sensitivity (ng/mL) | Detection range (ng/mL) |
Anti-Rituximab ELISA Kit (Mabthera®) | 30 | 62 - 500 | |
Anti-Trastuzumab ELISA Kit (Herceptin®) | 30 | 62 - 500 | |
Anti-Infliximab ELISA Kit (Remicade®) | 15 | 62 - 500 | |
Anti-Adalimumab ELISA Kit (Humira®) | 30 | 62 - 500 | |
Anti-Bevacizumab ELISA Kit (Avastin®) | 30 | 62 - 500 | |
Anti-Infliximab ELISA Kit (Remsima®) | 30 | 62 - 500 | |
Anti-Cetuximab ELISA Kit (Erbitux®) | 30 | 62 - 500 | |
Anti-Etanercept ELISA Kit (Enbrel®) | Qualitative | Qualitative | |
Anti-Golimumab ELISA Kit (Simponi®) | Qualitative | Qualitative | |
Anti-Denosumab ELISA Kit (Prolia®) | Qualitative | Qualitative | |
Anti-Omalizumab ELISA Kit (Xolair®) | Qualitative | Qualitative | |
Anti-Nivolumab ELISA Kit (Opdivo®) | Qualitative | Qualitative | |
Anti-Pembrolizumab ELISA Kit (Keytruda®) | Qualitative | Qualitative | |
Anti-Ipilimumab ELISA Kit (Yervoy®) | Qualitative | Qualitative | |
Anti-Filgrastim ELISA Kit (Neupogen®) | 3 | 3.1 - 50 | |
Anti-Avelumab ELISA Kit (Bavencio®) | Qualitative | Qualitative |